- Trials with a EudraCT protocol (77)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
77 result(s) found for: Endometrioid tumor.
Displaying page 1 of 4.
| EudraCT Number: 2015-001732-38 | Sponsor Protocol Number: 1502 | Start Date*: 2015-09-14 | |||||||||||
| Sponsor Name:CENTRE OSCAR LAMBRET | |||||||||||||
| Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ... | |||||||||||||
| Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001072-37 | Sponsor Protocol Number: IRFMN-EN-7556 | Start Date*: 2019-01-29 | |||||||||||||||||||||
| Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri | |||||||||||||||||||||||
| Full Title: AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/r... | |||||||||||||||||||||||
| Medical condition: Newly diagnosed, histologically-confirmed stage III-IV endometrial carcinoma/carcinosarcoma with residual disease after surgery, either measurable or evaluable, and naïve to first line systemic ant... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) DE (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2008-006841-25 | Sponsor Protocol Number: CRAD001CCH08t | Start Date*: 2009-08-24 | |||||||||||
| Sponsor Name:Oncology Institute of Southern Switzerland | |||||||||||||
| Full Title: Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer | |||||||||||||
| Medical condition: Recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001071-37 | Sponsor Protocol Number: LUC19-001 | Start Date*: 2019-08-06 |
| Sponsor Name:Cliniques Universitaires Saint-Luc | ||
| Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido | ||
| Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004455-17 | Sponsor Protocol Number: ESR-20-21103 | Start Date*: 2023-05-24 | |||||||||||
| Sponsor Name:VHIO Vall d’Hebron Institute of Oncology | |||||||||||||
| Full Title: Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Sta... | |||||||||||||
| Medical condition: Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002281-39 | Sponsor Protocol Number: GINECO-OV238 | Start Date*: 2020-11-18 | |||||||||||
| Sponsor Name:ARCAGY-GINCO | |||||||||||||
| Full Title: A GINECO phase II trial assessing the safety and efficacy of the Bevacizumab (FKB238), Olaparib (MEDI 4736) and Durvalumab combination in patients with advanced epithelial ovarian cancer in relapse... | |||||||||||||
| Medical condition: Patients with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at least one previous line of platinum-taxane chemotherapy, and present wi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-000518-39 | Sponsor Protocol Number: CO-338-014 | Start Date*: 2014-01-08 | |||||||||||||||||||||
| Sponsor Name:Clovis Oncology, Inc. | |||||||||||||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Se... | |||||||||||||||||||||||
| Medical condition: Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) ES (Ongoing) FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2010-023081-52 | Sponsor Protocol Number: ENGOT-EN2-DGCG | Start Date*: 2011-01-25 | ||||||||||||||||
| Sponsor Name:Danish Gynaecological Cancer Group (DGCG) | ||||||||||||||||||
| Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. | ||||||||||||||||||
| Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-000952-11 | Sponsor Protocol Number: PR-30-5017-C | Start Date*: 2016-07-01 | |||||||||||
| Sponsor Name:TESARO, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Base... | |||||||||||||
| Medical condition: Homologous recombination deficiency advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003779-36 | Sponsor Protocol Number: ICR-CTSU/2018/10066 | Start Date*: 2019-10-11 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:The Institute of Cancer Research | ||||||||||||||||||||||||||||||||||||||
| Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-004027-52 | Sponsor Protocol Number: GINECO-OV125b | Start Date*: 2015-11-30 | ||||||||||||||||
| Sponsor Name:ARCAGY Research | ||||||||||||||||||
| Full Title: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer trea... | ||||||||||||||||||
| Medical condition: Patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Ongoing) AT (Completed) BE (Completed) ES (Ongoing) DK (Completed) SE (Completed) FI (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2004-002429-37 | Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 | Start Date*: 2004-11-17 |
| Sponsor Name:Nordic Society for Gynecologic Oncology | ||
| Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. | ||
| Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001660-29 | Sponsor Protocol Number: FAB18 | Start Date*: 2019-01-16 | |||||||||||
| Sponsor Name:Leiden University Medical Center | |||||||||||||
| Full Title: FAB: Functional Analysis of BRCAness | |||||||||||||
| Medical condition: Recurrent epithelial ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000065-23 | Sponsor Protocol Number: C/30/2011 | Start Date*: 2018-06-05 | |||||||||||||||||||||
| Sponsor Name:Imperial College London | |||||||||||||||||||||||
| Full Title: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanc... | |||||||||||||||||||||||
| Medical condition: Ovarian, fallopian tube or primary peritoneal cancer of clear cell, endometrioid or high grade serous subtype or carcinosarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2013-000517-20 | Sponsor Protocol Number: CO-338-017 | Start Date*: 2013-11-26 | |||||||||||||||||||||
| Sponsor Name:Clovis Oncology, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||||||||||||||||||
| Medical condition: Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-000399-41 | Sponsor Protocol Number: NOGGO-ov42 | Start Date*: 2020-01-22 | |||||||||||
| Sponsor Name:NOGGO e. V. | |||||||||||||
| Full Title: Rucaparib MAintenance after Bevacizumab Maintenance following Carboplatin based first line chemotherapy in Ovarian Cancer patients | |||||||||||||
| Medical condition: This is a multicenter, randomized, placebo controlled, double blind study including patients with patients with histologically confirmed, advanced (FIGO stage IIIB, IIIC, or IV of the 2014 FIGO cla... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001637-39 | Sponsor Protocol Number: RP630601 | Start Date*: 2021-06-02 | |||||||||||
| Sponsor Name:Repare Therapeutics | |||||||||||||
| Full Title: Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination with RP-3500 in Patients with Advanced Solid Tumors | |||||||||||||
| Medical condition: Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001848-20 | Sponsor Protocol Number: ENGOT-EN3-NSGO/PALEO | Start Date*: 2016-09-28 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU) | ||||||||||||||||||||||||||||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Histological confirmed endometrial cancer of endometrioid type. Mixed tumor histology is allowed if the non-endometrioid component is less than 5%. Tumour must be estrogen receptor positive. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) FI (Completed) DE (Completed) ES (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-003883-36 | Sponsor Protocol Number: CFTSp104 | Start Date*: 2017-02-01 | |||||||||||
| Sponsor Name:The Christie NHS Foundation Trust | |||||||||||||
| Full Title: Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer | |||||||||||||
| Medical condition: platinum sensitive BRCAm high grade serous ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
